Big pharma sports smallest late-stage pipeline for a decade

Big pharma sports smallest late-stage pipeline for a decade

Source: 
EP Vantage
snippet: 

The pandemic could have come at a particularly bad time for big pharma. An Evaluate Vantage analysis shows that the number of novel, late-stage assets sitting in the pipelines of the world’s biggest drug makers is at a low for the decade, having been in decline for the last four years.